Yuanchen Liang

Yuanchen Liang

Auto-generated profile, based on publicly available information

Yuanchen Liang

School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales 2308, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
BBBeata Bajorek
Beata Bajorek
RSRawan Sawalha
Rawan Sawalha
YLYuanchen Liang
Yuanchen Liang
LGLakshy Ganesh
Lakshy Ganesh
MAMohamed Afifi
Mohamed Afifi

14 October 2022 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
CUChioma Uzoigwe
Chioma Uzoigwe
JNJosh Noone
Josh Noone
YLYuanjie Liang
Yuanjie Liang
SASarah Naz Ali
Sarah Naz Ali
CGCory Gamble
Cory Gamble
Introduction Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in patients with type 2 diabetes (T2D), but treatment discontinuation without new T2D therapy initiation may compromise outcomes. Methods This retrospective cohort study (July 1, 2012, to December 31, 2019) identified patients ≥ 18 years with T2D in the Optum® Clinformatics® Data Mart who discontinued liraglutide (index date). Patients with continuous enrollment for ≥ 12 months before and after discontinuation (baseline), ≥ 6 months liraglutide coverage pre-index, and no new T2D therapy start during follow-up were included. Changes from baseline in all-cause healthcare resource utilization (HCRU; outpatient visits, emergency room [ER] visits, and hospitalization events), costs, and glycated hemoglobin (HbA1c) over 12 months after discontinuation were evaluated. Results Overall, 625 of 186,630 patients who discontinued liraglutide during the baseline period (mean [standard deviation (SD)] age, 62.1 [10.1] years) were included in the 12-month analysis. A significant increase in the rate of ER visits (rate ratio [95% confidence interval (CI)]: 1.23 per 100 person-months [1.05, 1.43]; P = 0.0079), hospitalizations (1.36 [1.09, 1.70]; P = 0.0056), and outpatient visits (1.03 [1.01, 1.06]; P = 0.0075) was observed. Total HCRU costs significantly increased after discontinuation ($436.12 per patient per month [$90.07, $782.17]; P = 0.0136), driven by significantly higher outpatient costs ($238.70 [$34.16, $443.25]; P = 0.0223). HbA1c increased significantly by 12 months from mean (SD) 7.37 (1.53) at baseline to 7.63 (1.64; difference: + 0.25 [95% CI 0.14, 0.36]; P < 0.0001). Conclusions Patients who discontinued liraglutide showed increases in HCRU; costs, mainly driven by outpatient cost; and HbA1c within 12 months, emphasizing the importance of treatment optimization on clinical and economic outcomes in patients with T2D.

31 January 2025 in Current Treatment Options in Neurology
Verified
Journal Article
Open access
PDF file
YLY. Liang
Y. Liang
CLC. Levi
C. Levi
NSNeil Spratt
Neil Spratt
HJheidi Janssen
heidi Janssen
BBB. Bajorek
B. Bajorek
Purpose of Review: Three-quarters of stroke survivors experience fatigue, yet its management remains suboptimal due to uncertainty about therapeutic options and underpinning evidence. Given the diverse causes and varying patient preferences, various strategies—ranging from pharmacological to non-pharmacological treatments—are being explored. A clearer understanding of these options' effectiveness would help prioritize those most suitable for clinical evaluation. Recent Findings: Twenty studies involving 1,163 participants were extracted, including 12 randomized clinical trials, 2 non-randomized clinical trials, 1 post hoc follow-up study, and 5 treatment protocols or abstracts for studies. Most treatment options demonstrated significant improvements, reported as changes in fatigue and/or quality-of-life measurement scales (scores) or changes in the proportion of patients reporting an improvement. Variability in outcome measures precluded a comparison of efficacy between treatment options. Specific conventional mono-pharmacotherapies (e.g., modafinil) were shown to be most effective, reducing fatigue in up to 81% of patients whilst cognitive behaviour-based interventions reduced fatigue in 24–60% of stroke patients. Complementary therapies (acupuncture, Astragalus membranaceus) reduced fatigue scores by 42–45% and were most effective when used in combination therapies; Traditional Chinese medicine (Qi Supplementing Dominated Chinese Materia Medica) plus physical rehabilitation significantly reduced mean fatigue scores by 66%. Summary: Presently, conventional 。pharmacotherapies appear to be the most effective option for managing post-stroke fatigue. However, further trials are needed to confirm their long-term effectiveness, safety, cost-effectiveness, and patient acceptability. More research is necessary to explore the full and diverse range of treatment options.

6 August 2026 in Australian Psychologist
Verified
Journal Article
Open access
YLY. Liang
Y. Liang
CLC. Levi
C. Levi
STShinya Tomari
Shinya Tomari
CECarlos Garcia Esperon
Carlos Garcia Esperon
NSNeil Spratt
Neil Spratt
BBB. Bajorek
B. Bajorek
Globally, ischaemic stroke is one of the major causes of death and long-term disability, placing a substantial burden on individuals and healthcare systems (Feigin et al., 2021; Ovbiagele & Nguyen-...

11 August 2026 in International Journal of Pharmacy Practice
Verified
Journal Article
Open access
YLYuanchen Liang
Yuanchen Liang
CLChristopher Levi
Christopher Levi
BBBeata Bajorek
Beata Bajorek
Background: Post-stroke fatigue and mental health disorders are common but often overlooked. Health professionals’ perspectives play a critical role in recognizing, assessing, and managing these symptoms, which significantly influence recovery and quality of life. Objectives: To explore health professionals’ perspectives of post-stroke treatments and identify factors influencing treatment preferences. Methods: Vignette-based semi-structured interviews were conducted either in person or online/by telephone with health professionals, who were asked for their perspectives on four treatment vignettes using a 5-point Likert scale. Qualitative data were analysed thematically, and quantitative data were compared using non-parametric tests. Key themes were mapped to the Bio-Psycho-Social-Systems (BPSS) model to explore factors influencing treatment preferences. Key findings: Sixteen of 20 health professionals provided numerical ratings. There were no significant differences in ‘liking’ ratings for any fatigue or mental health vignette. CBT was most frequently the most preferred option for managing fatigue (90.0%), followed by modafinil (10.0%). For mental health, nortriptyline was most frequently the most preferred treatment (37.5%), followed by herbal medicines plus fluoxetine and acupuncture (25.0% each) and repetitive transcranial magnetic stimulation (12.5%). Five influencing themes were mapped to the BPSS model: therapeutic side effects and safety concerns (biological); evidence base and perceived efficacy (biological); accessibility and system practicality (systems); patient preferences (psychological/social); and professional scope and confidence (psychological/systems). Conclusion: Whilst health professionals were open to non-pharmacological strategies for managing post-stroke complications, conventional pharmacotherapy was preferred, either alone or in combination with other therapies, especially for severe mental health disorders.